THE PURPOSE OF THIS MODIFICATION IS TO CREATE ISOGENIC CELL CONTROL LINES FOR THE LINES CURRENTLY BEING CREATED.

NIH RePORTER · NIH · N01 · $149,500 · view on reporter.nih.gov ↗

Abstract

The New York Stem Cell Foundation (NYSCF) Research Institute and the NIH National Eye Institute (NEI) have generated induced Pluripotent Stem Cells (iPSCs) from age-related macular degeneration (AMD) patients, which are available for distribution to the vision research community. The patients are enrolled in the Age-Related Eye Disease Study (AREDS) and were selected by NEI. The initial lines have mutations in genes that are known to confer high risk towards developing AMD. The AREDS iPSC cohort will have its extensive clinical and medical data available to researchers and the hope is that phenotypic correlations with these lines will spur a better understanding of how AMD starts and progresses. PBMCs were isolated from whole blood, reprogrammed to iPSCs via Sendai virus, monoclonalized, expanded, and QC assays performed using the NYSCF Global Stem Cell Array®. iPSCs will be distributed with an SOP for thawing and expansion and a Certificate of Analysis (CoA).

Key facts

NIH application ID
10506171
Project number
263201800007C-P00004-9999-1
Recipient
NEW YORK STEM CELL FOUNDATION
Principal Investigator
SCOTT NOGGLE
Activity code
N01
Funding institute
NIH
Fiscal year
2021
Award amount
$149,500
Award type
Project period
2018-09-25 → 2022-03-24